相关实验视频

Updated: Jun 9, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

向NOX2和糖质代谢作为急性骨髓性白血病治疗策略

Carla Ijurko^1,2, Marta Romo-González^1,2,3, Rodrigo Prieto-Bermejo^1,2,4

¹Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, Plaza Doctores de la Reina, s/n, Salamanca, 37007, Spain.

Biomarker research

|October 29, 2024

概括

双重抑制NOX2和糖溶解在治疗急性髓性白血病 (AML) 中表现有前途. 这种综合方法显著降低了AML细胞的生长和存活率,提供了潜在的新疗法策略.

科学领域:

在瘤学瘤学.
癌症新陈代谢癌症新陈代谢
血液学恶性瘤是什么

背景情况:

急性髓性白血病 (AML) 是一种异质性癌症,存活率较低,需要新的治疗方法.
氧化应激和代谢变化是癌症的关键标志,NADPH氧化酶 (NOX) 可能将这些过程联系起来.
人们越来越认识到NOX2在AML代谢中的作用,这表明它是治疗点.

研究的目的:

研究同时抑制NOX2和AML中的糖解的治疗潜力.
评估对AML细胞增殖,克隆性潜力和细胞死亡的综合影响.
在患者衍生样本和体内模型中评估这种双重抑制的有效性.

主要方法:

在AML细胞系中,抑制NOX2与向关键的糖解酶 (hexokinase或乳酸脱酶 (LDH)) 相结合.
在AML患者的初级骨髓样本中进行验证.
在AML的体内小鼠模型中的评估.

主要成果:

双重抑制NOX2和糖解显著降低了AML细胞增殖和克隆性潜力.
在各种AML细胞系和来自患者的样本中观察到广泛的细胞死亡.
在体内AML模型中,NOX2和LDH联合抑制增强了cytarabine (AraC) 的疗效,并延长了存活时间.

结论:

同时准NOX2和糖解代表了AML的一种新且强效的治疗策略.
这种方法在临床前模型和患者样本中显示出显著的抗白血病效应.
组合疗法可能会提高传统的AML治疗的有效性,如AraC.

关键词:

CYBB CYBB 在线观看患有急性髓性白血病的人群.葡萄糖溶解是什么? 葡萄糖溶解这就是Hexokinase的作用.乳酸脱酶 (LDH) 的使用在NADPH氧化酶.氧二氧化 (NOX2) 是一种

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...